Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Antioxidant Supplementation Found To Be Beneficial In Men, But Not Women

This article was originally published in The Tan Sheet

Executive Summary

Low-dose antioxidant therapy produced a protective effect against cancer and all-cause mortality in men who took supplements over the long term, according to a recent study in the Archives of Internal Medicine

You may also be interested in...



Vitamin E Dose Increases Linked To Rise In Risk Of Death – Study

Negative results from a vitamin E study showing high doses of the supplement may lead to a greater risk of all-cause mortality increase industry anticipation of findings from ongoing prospective antioxidant trials

Vitamin E/Prostate Cancer Prevention Needs Further Study – ATBC Follow-Up

The possible preventive effects of alpha-tocopherol on prostate cancer "requires confirmation from other trials before public health recommendations can be made for vitamin E," researchers in the Alpha-Tocoperol, Beta-Carotene Cancer Prevention Study conclude in a postintervention follow-up review

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS097581

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel